What changed at CPC in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The archive
Page 170 of 170 of this archive, newest first.
Attribution is the hard part
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Spain health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to Australia after 5 consecutive customs detentions
The route did not close because of a rule about peptides.
SURMOUNT-OSA extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The submitted sample: the weakest link in the whole system
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
Why a 0.036-dalton difference is the hardest number in peptide identity
Parts per million sound impressive until they are converted into daltons at the molecular weight of the thing being measured.
Medutest result on a Xianning orforglipron lot lands 2.7 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The online reseller trading as Adamant Research Supply closes after 11 years
A proper account of an operation that existed, and of what closing it cost.
The 28-day notice: how a compounding wind-down works in Sweden
The document is four pages. Three of them are about dates.
Shenzhen export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Everything on the page, in the order a chemist would read it
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
What a 1 mL syringe does that a 0.3 mL syringe does not
A unit is a volume. A dose is a mass. The bridge between them is concentration, and concentration is a number somebody has to calculate.
Saudi Arabia caps liraglutide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What changed at Homopeptide in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at GL Biochem in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A design note on withdrawal trials, and why the run-in matters
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
What twenty companies say about storage, and what they have measured
What would make a difference is not a regulator. It is three lines on a certificate, all of which are already known to whoever wrote it.
Independent analysis puts a BCH semaglutide lot at 95.2%, against 91.2% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to Norway after 23 consecutive customs detentions
The route did not close because of a rule about peptides.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Background rates, and why they matter for attribution
The features that should prompt urgent assessment, stated once and plainly.
The tolerability data everybody quotes and nobody reads
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
A tested vial is evidence about a vial
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
VendorInvestigate result on a Hong Kong dulaglutide lot lands 2.0 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
What changed at WXT in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.